J Long1, Q Cai1, M Steinwandel2, M K Hargreaves3, S R Bordenstein4,5, W J Blot1,2, W Zheng1, X O Shu1. 1. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 2. International Epidemiology Institute, Rockville, MD, USA. 3. Department of Internal Medicine, Meharry Medical College, Nashville, TN, USA. 4. Department of Biological Sciences, Vanderbilt University, Nashville, TN, USA. 5. Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN, USA.
Abstract
BACKGROUND AND OBJECTIVE: The oral microbiome may help to maintain systemic health, including how it affects blood glucose levels; however, direct evidence linking the oral microbiome with diabetes is lacking. MATERIAL AND METHODS: We compared the oral microbiome profiles of 98 participants with incident diabetes, 99 obese non-diabetics and 97 normal weight non-diabetics, via deep sequencing of the 16S rRNA gene. RESULTS: We found that the phylum Actinobacteria was present significantly less abundant among patients with diabetes than among the controls (p = 3.9 × 10-3 ); the odds ratio (OR) and 95% confidence interval (CI) was 0.27 (0.11-0.66) for those individuals who had relative abundance higher than the median value. Within this phylum, five families and seven genera were observed, and most of them were less abundant among patients with diabetes. Notably, genera Actinomyces and Atopobium were associated with 66% and 72% decreased risk of diabetes with p-values of 8.9 × 10-3 and 7.4 × 10-3 , respectively. Stratified analyses by race showed that most taxa in this phylum were associated with diabetes in both black and white participants. This phylum was also less abundant among non-diabetic obese subjects compared to normal weight individuals, particularly genera Mobiluncus, Corynebacterium and Bifidobacterium, which showed p < 0.05. CONCLUSION: Our study revealed that multiple bacteria taxa in the phylum Actinobacteria are associated with the risk of type 2 diabetes. Some are also associated with the prevalence of obesity, suggesting that the oral microbiome may play an important role in diabetes etiology.
BACKGROUND AND OBJECTIVE: The oral microbiome may help to maintain systemic health, including how it affects blood glucose levels; however, direct evidence linking the oral microbiome with diabetes is lacking. MATERIAL AND METHODS: We compared the oral microbiome profiles of 98 participants with incident diabetes, 99 obese non-diabetics and 97 normal weight non-diabetics, via deep sequencing of the 16S rRNA gene. RESULTS: We found that the phylum Actinobacteria was present significantly less abundant among patients with diabetes than among the controls (p = 3.9 × 10-3 ); the odds ratio (OR) and 95% confidence interval (CI) was 0.27 (0.11-0.66) for those individuals who had relative abundance higher than the median value. Within this phylum, five families and seven genera were observed, and most of them were less abundant among patients with diabetes. Notably, genera Actinomyces and Atopobium were associated with 66% and 72% decreased risk of diabetes with p-values of 8.9 × 10-3 and 7.4 × 10-3 , respectively. Stratified analyses by race showed that most taxa in this phylum were associated with diabetes in both black and white participants. This phylum was also less abundant among non-diabetic obese subjects compared to normal weight individuals, particularly genera Mobiluncus, Corynebacterium and Bifidobacterium, which showed p < 0.05. CONCLUSION: Our study revealed that multiple bacteria taxa in the phylum Actinobacteria are associated with the risk of type 2 diabetes. Some are also associated with the prevalence of obesity, suggesting that the oral microbiome may play an important role in diabetes etiology.
Authors: T Z DeSantis; P Hugenholtz; N Larsen; M Rojas; E L Brodie; K Keller; T Huber; D Dalevi; P Hu; G L Andersen Journal: Appl Environ Microbiol Date: 2006-07 Impact factor: 4.792
Authors: Yael Haberman; Timothy L Tickle; Phillip J Dexheimer; Mi-Ok Kim; Dora Tang; Rebekah Karns; Robert N Baldassano; Joshua D Noe; Joel Rosh; James Markowitz; Melvin B Heyman; Anne M Griffiths; Wallace V Crandall; David R Mack; Susan S Baker; Curtis Huttenhower; David J Keljo; Jeffrey S Hyams; Subra Kugathasan; Thomas D Walters; Bruce Aronow; Ramnik J Xavier; Dirk Gevers; Lee A Denson Journal: J Clin Invest Date: 2014-07-08 Impact factor: 14.808
Authors: P M Preshaw; A L Alba; D Herrera; S Jepsen; A Konstantinidis; K Makrilakis; R Taylor Journal: Diabetologia Date: 2011-11-06 Impact factor: 10.122
Authors: Yaohua Yang; Wei Zheng; Qiu-Yin Cai; Martha J Shrubsole; Zhiheng Pei; Robert Brucker; Mark D Steinwandel; Seth R Bordenstein; Zhigang Li; William J Blot; Xiao-Ou Shu; Jirong Long Journal: J Epidemiol Community Health Date: 2019-09-28 Impact factor: 3.710
Authors: Delicia Shu-Qin Ooi; Cheryl Pei-Ting Tan; Michelle Jia-Yu Tay; Siong Gim Ong; Elizabeth Huiwen Tham; Kewin Tien Ho Siah; Johan Gunnar Eriksson; Keith M Godfrey; Lynette Pei-Chi Shek; Evelyn Xiu-Ling Loo Journal: J Dev Orig Health Dis Date: 2020-06-15 Impact factor: 2.401
Authors: R M Clancy; M C Marion; H C Ainsworth; M J Blaser; M Chang; T D Howard; P M Izmirly; C Lacher; M Masson; K Robins; J P Buyon; C D Langefeld Journal: J Autoimmun Date: 2019-10-31 Impact factor: 7.094